Nathan D. Jorgensen

CIK: 0001842523

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (40.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (60.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

VYGR

Voyager Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

VYGR
Voyager Therapeutics, Inc.
Feb 24, 2026
Sale(S)
Direct
4.7K shares at avg. $3.77$18K
VYGR
Voyager Therapeutics, Inc.
Feb 6, 2026
Award(A)
Direct
32.3K shares-
VYGR
Voyager Therapeutics, Inc.
Oct 3, 2025
Sale(S)
Direct
7.7K shares at avg. $4.78$37K
VYGR
Voyager Therapeutics, Inc.
Feb 21, 2025
Award(A)
Direct
51.5K shares-
VYGR
Voyager Therapeutics, Inc.
Oct 1, 2024
Award(A)
Direct
80K shares-

		Type	Shares	Price		Ownership
Feb 24, 2026	VYGR Voyager Therapeutics, Inc.	Sale(S)	4,668	$3.77	$17,598	Direct
Feb 6, 2026	VYGR Voyager Therapeutics, Inc.	Award(A)	32,250	-	$0	Direct
Oct 3, 2025	VYGR Voyager Therapeutics, Inc.	Sale(S)	7,666	$4.78	$36,643	Direct
Feb 21, 2025	VYGR Voyager Therapeutics, Inc.	Award(A)	51,500	-	-	Direct
Oct 1, 2024	VYGR Voyager Therapeutics, Inc.	Award(A)	80,000	-	$0	Direct

1-5 of 5 transactions

About Jorgensen Nathan D.

Jorgensen Nathan D. (SEC CIK 0001842523) files insider reports with the SEC as Chief Financial Officer of Voyager Therapeutics, Inc. (VYGR).

Signal8 holds 5 ownership filings by Jorgensen Nathan D., all Form 4s, filed between Oct 2, 2024 and Feb 26, 2026. Those filings report 5 transactions, from Oct 1, 2024 to Feb 24, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Jorgensen Nathan D.'s filings is in LEXINGTON, MA.

Recent filings by Jorgensen Nathan D.

Feb 24, 2026: Open-market sale of VYGR shares (Form 4, code S).
Feb 6, 2026: Grant or award of VYGR shares (Form 4, code A).
Oct 3, 2025: Open-market sale of VYGR shares (Form 4, code S).
Feb 21, 2025: Grant or award of VYGR shares (Form 4, code A).
Oct 1, 2024: Grant or award of VYGR shares (Form 4, code A).

Other insiders filing for Voyager Therapeutics, Inc. (VYGR)

SCANGOS GEORGE A, Director
MACKEY CATHERINE J, Director
Hyman Steven, Director
Vitale Nancy, Director
Higgins Michael J, Director
Onyia Jude, Director

How to read Form 4 transaction codes